Immunoreactivity of Stat5 Phosphorylated on Tyrosine as a Cell-Based Measure of Bcr/Abl Kinase Activity

Cytometry Part A

Volumn 54, Issue 2, 2003, Pages 75-88

  Jacobberger, James W ^a   Sramkoski, R Michael ^a   Frisa, Phyllis S ^a   Ye, Peggy Peng ^a   Gottlieb, Megan A ^a   Hedley, David W ^b   Shankey, T Vincent ^c   Smith, Bradley L ^d   Paniagua, Mary ^e   Goolsby, Charles L ^e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c BECKMAN COULTER INC   (United States)

^d CELL SIGNALING TECHNOLOGY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cell cycle expression; Gleevec; Leukemia; Signal transduction; STI 571

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BCR ABL PROTEIN; BCR ABL PROTEIN KINASE; CELL ANTIGEN; EPITOPE; FORMALDEHYDE; IMATINIB; JANUS KINASE; METHANOL; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LEUKEMIA CELL; MEASUREMENT; MITOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 10744220539     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.10063     Document Type: Article

References (41)

1. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-dependent cyclin D1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000;3:299-305.
2. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19:2496-2504.
3. Wong S, Witte ON. Modeling Philadelphia chromosome positive leukemias. Oncogene 2001;20:5644-5659.
4. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-254.
5. Carlesso N, Frank, DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811-820.
6. Ilaria Jr RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-31710.
7. Chai S, Nichols G, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997;159:4720-4728.
8. Hagiwara S, Iki S, Urabe A, Saeki K, Miwa A, Togawa A, Ozawa K, Takaku F, Yuo A. Tyrosine phosphorylation of proteins in primary human myeloid leukemia cells stimulated by cytokines: analysis of the frequency of phosphorylation, and partial identification and semi-quantification of signaling molecules. Int J Hematol 1998;68:387-401.
9. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, Rothammer K, Roussel MF, Ihle JN. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 2000;96:2277-2283.
10. Brockman JL, Schroeder MD, Schuler LA. PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 2002;16:774-784.
11. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, Kanakura Y. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. Embo J 1999;18:1367-1377.
12. Wen X, Lin HH, Shih HM, Kung HJ, Ann DK. Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J Biol Chem 1999;274:38204-38210.
13. Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M. Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. Br J Haematol 2000;110:663-673.
14. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-1065.
15. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-984.
16. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118-2125.
17. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationany developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
18. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002;100:435-441.
19. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-1971.
20. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989;73:1272-1278.
21. Koistinen P, Wang C, Yang GS, Wang YF, Williams DE, Lyman SD, Minden MD, McCulloch EA. OCI/AML-4 an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside. Leukemia 1991;5:704-711.
22. Drexler HG, MacLeod RA, Uphoff CC. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res 1999;23:207-215.
23. Schimenti KJ, Jacobberger JW, Fixation of mammalian cells for flow cytometric evaluation of DNA content and nuclear immunofluores-cence. Cytometry 1992;13:48-59.
24. Jacobberger JW, Fogleman D, Lehman JM. Analysis of intracellular antigens by flow cytometry. Cytometry 1986;7:356-364.
25. Sramkoski RM, Wormsley SW, Bolton WE, Crumpler DC, Jacobberger JW. Simultaneous detection of cyclin B1, p105, and DNA content provides complete cell cycle phase fraction analysis of cells that endoreduplicate. Cytometry 1999;35:274-283.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
27. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
28. Jacobberger JW, Stoichiometry of immunocytochemical staining reactions. Methods Cell Biol 2001;63:271-298.
29. Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, Leonard WJ. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995;2:331-339
30. Jacobberger JW, Sramkoski RM, Zhang D, Zumstein LA, Doerksen LD, Merritt JA, Wright SA, Shults KE. Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy. Cytometry 1999;38:201-213.
31. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
32. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999;189:1229-1242.
33. Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001;20:6188-6195.
34. Fleisher TA, Dorman SE, Anderson JA, Vail M, Brown MR, Holland SM. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol 1999;90:425-430.
35. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-1152.
36. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001;46:72-78.
37. Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of intracellular phosphorylated STAT-4 by flow cytometry. Clin Immunol 2001;100:270-276.
38. Ishida R, Iwai M, Marsh KL, Austin CA, Yano T, Shibata M, Nozaki N, Hara A. Threonine 1342 in human topoisomerase II alpha is phosphorylated throughout the cell cycle. J Biol Chem 1996;271:30077-30082.
39. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 2002;20:155-162.
40. Advani AS, Pendergast AM. Bcr-Abl variants: biological and clinical aspects. Leuk Res 2002;26:713-720.
41. Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 1997;8:63-79.